In the BioHarmony Drug Report Database

"Preview" Icon

Lurasidone

Latuda (lurasidone) is a small molecule pharmaceutical. Lurasidone was first approved as Latuda on 2010-10-28. It is used to treat bipolar disorder, major depressive disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. The pharmaceutical is active against 5-hydroxytryptamine receptor 7. In addition, it is known to target alpha-2C adrenergic receptor, alpha-2A adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, and 5-hydroxytryptamine receptor 1A. Latuda’s patents are valid until 2031-05-23 (FDA).

 

Trade Name

 

Latuda
 

Common Name

 

lurasidone
 

ChEMBL ID

 

CHEMBL1237021
 

Indication

 

bipolar disorder, major depressive disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Antipsychotic with binding activity on serotonin (5HT2A) and dopamine (D2) receptors

Image (chem structure or protein)

Lurasidone structure rendering